Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1105 participants.
Also called NCT03036462
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,105 participants
- Sponsor
- Registry
-
NCT03036462
-
- Other papers using this trial's data
- Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial
- Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany, Hungary, Italy, Poland, Portugal, Slovenia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT03036462. Randomized; triple masking; primary purpose treatment. Start 2017-03-07 (actual); primary completion 2024-05-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
- Acronym
- FAIR-HF2
- Condition
- Systolic Heart Failure
- Condition
- Iron Deficiency
- Intervention (Drug)
- Iron
- Intervention (Drug)
- Saline
- Lead sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Collaborator
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator
- Charite University, Berlin, Germany
Record details
- Record id
cardio:ct-nct03036462- Content hash
487218b4c0013bb635583974130540008bb633cf5491e2b0f62987fad8b93b16